Literature DB >> 9440716

Cancer patients use of nonproven therapy: a 5-year follow-up study.

T Risberg1, E Lund, E Wist, S Kaasa, T Wilsgaard.   

Abstract

PURPOSE: To investigate the prospective pattern of use of alternative medicine, here called nonproven therapy (NPT), among oncologic patients during a 5-year period, and the relationship between this use and survival, a questionnaire-based follow-up study was performed at the Department of Oncology, University of Tromsø, from 1990 to 1996. PATIENTS AND METHODS: Two-hundred fifty-two patients answered the first questionnaire during the period July 1990 to July 1991. Eligible patients were mailed follow-up questionnaires after 4, 12, 24 and 60 months. A telephone interview performed after the last follow-up questionnaire showed little disagreement with the prospective collected information as regards the number of patients reported as users of NPT (kappa, 0.92).
RESULTS: The number of patients who reported ever using NPT in each cross-sectional part of the study varied between 17.4% and 27.3%. However, the estimated cumulative risk of being a user of NPT during the follow-up period was 45%. Seventy-four percent of NPT users in this north Norwegian study population used faith healing or healing by hand (spiritual NPT) alone or in combination with other forms of NPT. The proportion of patients who used spiritual versus nonspiritual forms of NPT was consistent throughout the follow-up period. Women were more often users than men (50% v 31%, P = .002). Patients older than 75 years of age seldomly used NPT. The 5-year observed survival rate was not influenced by the use of NPT. Adjusted for sex, age, and diagnosis, patients with a high educational level had a borderline higher 5-year survival rate than patients with less education (P = .06).
CONCLUSION: Our results demonstrate that cross-sectionally designed studies will underestimate the number of ever-users of NPT in a cancer patient population. The use of NPT does not influence observed survival among cancer patients seen in north Norway.

Entities:  

Mesh:

Year:  1998        PMID: 9440716     DOI: 10.1200/JCO.1998.16.1.6

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

1.  Is it time for oncologists to modify their laissez-faire attitude toward alternative/complementary 'drug therapy'?

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

2.  Use of non-conventional medicine two years after cancer diagnosis in France: evidence from the VICAN survey.

Authors:  Aline Sarradon-Eck; Anne-Déborah Bouhnik; Dominique Rey; Marc-Karim Bendiane; Laetitia Huiart; Patrick Peretti-Watel
Journal:  J Cancer Surviv       Date:  2017-02-01       Impact factor: 4.442

3.  Any difference? Use of a CAM provider among cancer patients, coronary heart disease (CHD) patients and individuals with no cancer/CHD.

Authors:  Agnete E Kristoffersen; Arne J Norheim; Vinjar M Fønnebø
Journal:  BMC Complement Altern Med       Date:  2012-01-12       Impact factor: 3.659

Review 4.  Treatment options in hormone-refractory prostate cancer: current and future approaches.

Authors:  K A Harris; D M Reese
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway.

Authors:  A Kolstad; T Risberg; Y Bremnes; T Wilsgaard; H Holte; O Klepp; O Mella; E Wist
Journal:  Support Care Cancer       Date:  2004-02-06       Impact factor: 3.603

6.  The association between mental distress and the use of alternative medicine among cancer patients in North Norway.

Authors:  T Risberg; B K Jacobsen
Journal:  Qual Life Res       Date:  2003-08       Impact factor: 4.147

7.  Piperine induces apoptosis of lung cancer A549 cells via p53-dependent mitochondrial signaling pathway.

Authors:  Yi Lin; Jianping Xu; Hehe Liao; Lu Li; Lei Pan
Journal:  Tumour Biol       Date:  2013-11-24

8.  The roles of herbal remedies in survival and quality of life among long-term breast cancer survivors--results of a prospective study.

Authors:  Huiyan Ma; Catherine L Carpenter; Jane Sullivan-Halley; Leslie Bernstein
Journal:  BMC Cancer       Date:  2011-06-06       Impact factor: 4.430

9.  Complementary and Alternative Medicine Use among Norwegian Cancer Survivors: Gender-Specific Prevalence and Associations for Use.

Authors:  Agnete E Kristoffersen; Arne J Norheim; Vinjar M Fønnebø
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-28       Impact factor: 2.629

10.  Potential health risks of complementary alternative medicines in cancer patients.

Authors:  U Werneke; J Earl; C Seydel; O Horn; P Crichton; D Fannon
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.